Summit Therapeutics Inc (SMMT)

09:30 AM

Can Summit Therapeutics Stock Double Your Money? - Yahoo Finance

09:30 AM

May 06, 2025

Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know - Yahoo

May 06, 2025

May 06, 2025

(SMMT) Trading Advice - news.stocktradersdaily.com

May 06, 2025

May 04, 2025

Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial - MSN

May 04, 2025

May 04, 2025

Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? - Benzinga

May 04, 2025

May 04, 2025

Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil - MSN

May 04, 2025

May 04, 2025

Why Summit Therapeutics Inc. (SMMT) Soared Last Week - Insider Monkey

May 04, 2025

May 04, 2025

These 10 Firms Soared Last Week, Here’s Why - Insider Monkey

May 04, 2025

May 03, 2025

Summit Therapeutics outlines ivonescimab progress with key Phase III data expected mid-2025 - MSN

May 03, 2025

May 02, 2025

Summit Therapeutics (SMMT) Stock: Goldman Sachs Raises Price Target | SMMT Stock News - GuruFocus

May 02, 2025

May 02, 2025

Summit Therapeutics: Promising Clinical Developments and Financial Stability Drive Buy Rating - TipRanks

May 02, 2025

May 02, 2025

Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus

May 02, 2025

May 02, 2025

Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2025 Earnings Call Transcript - Insider Monkey

May 02, 2025

May 02, 2025

This Soaring Stock Just Delivered More Good News. Time to Buy? - The Globe and Mail

May 02, 2025

May 02, 2025

Summit Therapeutics (SMMT) Advances with Ivonescimab in Key Tria - GuruFocus

May 02, 2025

May 02, 2025

Summit Therapeutics Reports Q1 2025 Progress and Financials - TipRanks

May 02, 2025

May 02, 2025

Summit Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 02, 2025

May 01, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

May 01, 2025

May 01, 2025

Summit Therapeutics (SMMT) Beats Q1 Earnings Expectations - GuruFocus

May 01, 2025

May 01, 2025

Summit Therapeutics Inc Reports Q1 2025 EPS of $(0.09), Aligning with Estimates; Revenue Unreported - GuruFocus

May 01, 2025

May 01, 2025

Summit Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 01, 2025

May 01, 2025

Summit Therapeutics Reports Financial Results and Operational Pr - GuruFocus

May 01, 2025

May 01, 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 | SMMT Stock News - GuruFocus

May 01, 2025

May 01, 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 - Business Wire

May 01, 2025

May 01, 2025

Summit Therapeutics (SMMT) Sees Balanced Options Activity Ahead - GuruFocus

May 01, 2025

Apr 30, 2025

Summit Therapeutics (SMMT) Earnings Report Expected Amidst Mixed Forecasts - GuruFocus

Apr 30, 2025

Apr 30, 2025

Summit Therapeutics (NasdaqGM:SMMT) Sees 16% Stock Price Increase Over Past Month - Yahoo Finance

Apr 30, 2025

Apr 28, 2025

Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga

Apr 28, 2025

Apr 28, 2025

Summit Therapeutics, Intel among Monday’s market cap stock movers By Investing.com - Investing.com South Africa

Apr 28, 2025

Apr 28, 2025

Summit Therapeutics, Intel among Monday’s market cap stock movers - Investing.com

Apr 28, 2025

Apr 28, 2025

Summit Therapeutics stock holds $44 target despite drop - Investing.com

Apr 28, 2025

Apr 28, 2025

Summit Therapeutics stock holds $44 target despite drop By Investing.com - Investing.com India

Apr 28, 2025

Apr 28, 2025

Summit Therapeutics stock holds $40 target at Citizens JMP By Investing.com - Investing.com Canada

Apr 28, 2025

Apr 28, 2025

Summit Therapeutics stock holds $40 target at Citizens JMP - Investing.com

Apr 28, 2025

Apr 28, 2025

Summit Therapeutics Shares Tumble Amid Trial Data Concerns - TipRanks

Apr 28, 2025

Apr 28, 2025

Summit Therapeutics (SMMT) Maintains Buy Rating Despite Market O - GuruFocus

Apr 28, 2025

Apr 28, 2025

Summit Therapeutics (SMMT) Maintains Buy Rating Despite Market Overreaction | SMMT Stock News - GuruFocus

Apr 28, 2025

Apr 28, 2025

Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Monday? - MSN

Apr 28, 2025

Apr 27, 2025

Summit Therapeutics (SMMT) Shares Plummet After Survival Data Di - GuruFocus

Apr 27, 2025

Apr 26, 2025

Akeso survival data for ivonescimab misses expectations, STAT says - Yahoo Finance

Apr 26, 2025

Apr 26, 2025

Summit Therapeutics: New Ivonescimab Data Raise Concerns (NASDAQ:SMMT) - Seeking Alpha

Apr 26, 2025

Apr 26, 2025

Summit Therapeutics Stock Plummets Amid Study Setback - Evrim Ağacı

Apr 26, 2025

Apr 26, 2025

BioNTech And Summit Therapeutics Stocks Fluctuate Dramatically - Evrim Ağacı

Apr 26, 2025

Apr 26, 2025

Summit Therapeutics (SMMT) Reports Ivonescimab's Approval in Chi - GuruFocus

Apr 26, 2025

Apr 25, 2025

Summit Therapeutics (SMMT) Observes Notable Progress with Ivones - GuruFocus

Apr 25, 2025

Apr 25, 2025

Summit Therapeutics, Saia, And T-Mobile US Take A Hit In Trading - Finimize

Apr 25, 2025

Apr 25, 2025

Akeso (AKESF) and Summit Therapeutics (SMMT) See Stock Declines After Drug Data Release | BNTX Stock News - GuruFocus

Apr 25, 2025

Apr 25, 2025

Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials - TipRanks

Apr 25, 2025

Apr 25, 2025

Merck (MRK) Reacts to Summit Therapeutics' Lung Cancer Therapy D - GuruFocus

Apr 25, 2025

Apr 25, 2025

Market Today: Alphabet's Earnings Boost Tech, Summit Therapeutics Plummets - GuruFocus

Apr 25, 2025